AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...

UBS has upgraded AstraZeneca (NASDAQ:AZN) to buy from neutral, stating it believes the company's in-market growth potential has been underestimated. The investment bank said its forecasts for the ...

AstraZeneca has been boosted by results from ASCO which show its Lynparza could expand its use beyond ovarian cancer. Results from a phase 3 trial presented today showed that patients treated with ...

AstraZeneca and Merck & Co’s Lynparza will be made available to prostate and breast cancer patients in England and Wales, after cost-effectiveness assessor NICE backed extending its use beyond ...

AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...

The KEYLYNK-001 study evaluated Keytruda in combination with chemotherapy (paclitaxel and carboplatin) followed by Keytruda with maintenance Lynparza, with or without Avastin (bevacizumab), for ...

John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual combination of paxalisib and immunotherapy could advance the treatment of ...

Klaus joins Epitopea after serving as Chief Development Officer (CDO) at Nykode Therapeutics, where he oversaw clinical development, regulatory affairs, and project management across oncology, ...